Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.
Human immunodeficiency virus type 1 subtype B and C proteases were manipulated to contain 90M, 88D, or 89L, and their in vitro biological properties were studied. We showed that D30N has significantly more impact in subtype C than in subtype B counterparts, accounting for the reported low prevalence of this mutation in patients failing nelfinavir-based regimens.
Gonzalez
Luis M F
LM
Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, CCS, Bloco A, Cidade Universitária, Ilha do Fundão, 21944-970 Rio de Janeiro, RJ, Brazil.
Brindeiro
Rodrigo M
RM
Aguiar
Renato S
RS
Pereira
Helena S
HS
Abreu
Celina M
CM
Soares
Marcelo A
MA
Tanuri
Amilcar
A
D002460:Cell Line; D003001:Cloning, Molecular; D017931:DNA Primers; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D007527:Isoenzymes / Q000235:genetics; D009154:Mutation / Q000235:genetics*; D019888:Nelfinavir / Q000494:pharmacology*; D010641:Phenotype; D012367:RNA, Viral / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014779:Virus Replication / Q000187:drug effects
D017931:DNA Primers; D017320:HIV Protease Inhibitors; D007527:Isoenzymes; D012367:RNA, Viral; D011993:Recombinant Fusion Proteins; D016333:HIV Protease; D019888:Nelfinavir